Ascendis Pharma A/S (A1SN34 SA) stock market data APIs
R$91.7192
0(0%)
as of July 14, 2026
Try our APIs with
free plan!
Ascendis Pharma A/S Financial Data Overview
Price chart is built with
Anychart
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Prev. Close
91.7192
Open
91.7192
High
91.7192
Low
91.7192
52 wk Range
61.62-94.05
Market Cap
6 048 M
P/E Ratio
2.064
Shares Outstanding
65 593 K
Revenue
866 M
Beta
0.485
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ascendis Pharma A/S data using free add-ons & libraries
Get Ascendis Pharma A/S Fundamental Data
Ascendis Pharma A/S Fundamental data includes:
- Net Revenue: 866 M
- EBITDA: -10 224 000
- Earnings Per Share: 44
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ascendis Pharma A/S News
New
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Ascendis Pharma reported new two-year radiographic outcomes from its pivotal ApproaCH trial...
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24%
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ascendis Pharma stock has climbed 24.0% over the past month, yet the current valuati...
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking lower late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
Ascendis Pharma Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104 Greater improvements observ...
Get Ascendis Pharma A/S fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
